ClinicalTrials.gg
TerminatedNCT05297032Updated Jan 10, 2023

Effects of Quercetin on Metabolic Health

An interventional study of Quercetin Phytosome in Quercetin, Lipid Metabolism and Aging, sponsored by Thorne HealthTech, Inc. Terminated at 1 site in United States. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Thorne HealthTech, Inc · Not applicable, Interventional, and Basic science

How we know

Why this study was terminated
Labs ordering channel is no longer available. Indena (collaborator) opted not to increase funding for an alternative, terminated study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Study summary

Quercetin is a natural flavonoid compound widely found in vegetables, fruits, and nuts. It has a long history of use as a dietary supplement. This study aims to assess results from a computational model suggesting that quercetin may offer novel benefits to metabolic health. Participants will take quercetin (as Quercetin Phytosome, a proprietary formulation with enhanced absorption properties) for 90 days while keeping lifestyle habits consistent throughout to estimate net effects of quercetin as much as possible. Blood samples will be collected at the beginning and end of the study to assess the effects of quercetin supplementation on metabolic health metrics such as LDL cholesterol, blood sugar, liver, kidney and immune function and calculated metabolic age. In addition, questionnaires will be completed to ensure compliance with study requirements and assess potential quercetin benefits in the participants' quality of life. This work will provide a proof-of-concept from a computational model of nutraceutical compounds and proposes a new application of quercetin in support of healthy human metabolism.

Read the detailed description

Following intake and enrollment steps, including providing consent, and approximately one week before other study activities begin, participants will submit an online questionnaire to collect baseline data about lifestyle factors such as diet, exercise, sleep, stress, and general quality of life. During this period they will also receive the study supplement and schedule their first blood draw at a local-to-them Quest Diagnostics facility. Participants will begin taking the study supplement on the day after their first blood draw. Study dosing consists of one capsule of Quercetin Phytosome (Thorne Research, Inc.; 250 mg) taken three times per day with meals for 90 days. Approximately one week after beginning to take study doses, and bi-weekly thereafter, participants will complete an online questionnaire to monitor lifestyle and quality of life factors. The final questionnaire will be completed on the day of or the day after the last study dose is taken. The day after the last study dose, participants will complete a second blood draw at Quest Diagnostics.

02

Conditions studied

  • Quercetin
  • Lipid Metabolism
  • Aging

Keywords

  • Quercetin
  • Quercetin Phytosome
  • Quercefit
  • Sophora japonica
  • Lipids
  • LDL
  • HDL
  • LDL Particles
  • Triglycerides
  • Cholesterol
  • Metabolic Age
  • Biological Age
  • Metabolic Health
  • Metabolism
  • Blood Test
03

In context

Lead sponsor

Thorne HealthTech, Inc is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 20-70 years
  • Self-report that, within the past 6 months, a medical professional has informed them of, or a blood test result has shown high-healthy Low Density Lipoprotein (LDL) levels (preferred range, if known: 130-159 mg/dL)

AND 2 or more of the following 4 (values are preferred, if known):

  • Low-healthy fasting High Density Lipoprotein (HDL \< 50 mg/dL)
  • High-healthy fasting Triglycerides (TG 150-199 mg/dL)
  • High-healthy fasting Blood Sugar (Glucose 100-126 mg/dL)
  • Waist Circumference > 40 in for men or > 35 in for women (this may be self-measured)

Also

  • Willing and able to travel to a Quest location for both blood draws
  • Willing and able to fast (except water) for 12 hours prior to each blood draw
  • Willing and able to comply with the study schedule (+/- 2 days)
  • Willing and able to complete online questionnaires
  • Willing and able to check email for study-related messages regularly (daily) and to use email as the primary means of communication for non-emergency study-related contact with the study team
  • to participate in the study discussed and signed
  • Willing and able to avoid making changes to diet, sleep, stress, exercise, and other lifestyle factors that may influence the study metrics
  • Willing and able to avoid use of the following supplements during the study:

    • Quercetin, Berberine, Red Yeast Rice, Fish Oil, Bergamot Juice Extract, Pantethine, Vitamin D3 dosing over 5,000IU daily, Pterostilbene, Aged Garlic, Phytosterols, Niacin (crystalline/acid, not niacinamide), Meriva/curcumin/turmeric

Exclusion criteria

Exclusion Criteria:

  • Individuals who live in NY, NJ, RI, SD, ND, HI, or MD (due to lack of availability of WellnessFX or Quest services)
  • Individuals who are currently taking any lipid-lowering medications (including statins) or have taken them within the past 6 months.
  • Individuals who are currently taking or have taken any lipid-lowering supplements (including quercetin) consistently in the past 4 weeks. Excluded supplements are products that contain:

    o Berberine, Red Yeast Rice, Fish Oil, Bergamot Juice Extract, Pantethine, Vitamin D3 dosing over 5,000IU daily, Pterostilbene, Aged Garlic, Phytosterols, Niacin (crystalline/acid, not niacinamide), Meriva/curcumin/turmeric

  • Diagnosed with metabolic syndrome
  • Being treated for hypertension
  • Known allergy or sensitivity to any components of the trial's nutritional supplement
  • Myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, or stent within five years
  • Known clinical coronary heart disease symptoms
  • Known clinical angina
  • History of cerebrovascular accident
  • Creatinine > 2.5 mg/dL
  • Chronic liver disease with , ALT, or alkaline phosphatase over 1.5 times normal
  • Known cancer within two years
  • Clinical congestive heart failure (systolic or diastolic CHF)
  • Type 1 or type 2 diabetes mellitus
  • Habitual drinking (cutoff at PI discretion using the following guidelines: 8 or more drinks a week) or being a current smoker/vaping
  • Pregnant or nursing
  • Women of child-bearing age not using an approved
  • Planned major surgery during the study (1 week before first blood draw and during the 90-day supplementation)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Quercetin Phytosome

    All participants will receive Quercetin Phytosome

    Dietary Supplement: Quercetin Phytosome

Interventions

  • Dietary supplementQuercetinStudies of QuercetinQuercetin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will ingest 1 capsule of Quercetin Phytosome (250 mg) three times daily with meals for 90 days.

    Also known as: Quercetin, Quercefit, Sophora japonica extract (flower)

06

What researchers measure

Primary outcomes

  1. Change in Biological Age score from before (day 0) to after (day 90) supplementation

    Quantitative changes before and after intervention in calculated metrics of biological age. These metrics are calculated by applying the Klemera-Doubal algorithm to a proprietary set of clinical measures. (Scale for each metric: 0-120) (ref: https://academic.oup.com/biomedgerontology/article/74/Supplement_1/S52/5625183?login=true)

    Time frame: 90 days

  2. Change in Apolipoprotein B from before (day 0) to after (day 90) supplementation

    Quantitative changes before and after intervention in Apolipoprotein B test (Quest Diagnostics 91726) (Scale: mg/dL)

    Time frame: 90 days

  3. Change in Lipoprotein Fractions from before (day 0) to after (day 90) supplementation

    Quantitative changes before and after intervention in Lipoprotein Fractionation, Ion Mobility test (Quest Diagnostics 91604) (Scale: particle number)

    Time frame: 90 days

  4. Quality of Life scale changes from before (day 0) to after (day 90) supplementation

    Quantitative changes in The Quality of Life Scale (Scale: 1-100 as determined by ref: http://www.jstor.org/stable/4034400)

    Time frame: 90 days

Secondary outcomes

  1. Lifestyle changes from before (day 0) to after (day 90) supplementation

    Quantitative changes among any time points in metrics of lifestyle measured by questionnaire. Questionnaire metrics and scales: Stress: 1-10 (little or none:1, extreme:10) Exercise: 1-10 (little or none:1, extreme:10) Diet: 1-10 (very unhealthy:1, very healthy:10) Sleep: 1-10 (very poor:1, excellent:10)

    Time frame: 90 days

07

Study locations

1 site
  • This is a remote study - participants will find a commercial lab location near them.
    Summerville, South Carolina 29486, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Aug 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Mar 25, 2022
StartActual
Mar 24, 2022
Primary completionActual
Aug 31, 2022
CompletionActual
Sep 2, 2022
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05297032
Lead sponsor
Thorne HealthTech, Inc
Collaborators
Indena S.p.A
Responsible party
Sponsor
First posted
Mar 25, 2022
Start date
Mar 24, 2022
Primary completion
Aug 31, 2022
Completion
Sep 2, 2022
Last update
Jan 10, 2023

Study contacts

Stephen Phipps, ND, PhD
principal investigator · Thorne HealthTech, Inc
Loukia Lili, PhD
principal investigator · Thorne HealthTech, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Quercetin

Start the discussion